NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $3.06 +0.20 (+6.99%) Closing price 04:00 PM EasternExtended Trading$3.04 -0.02 (-0.49%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioLineRx Stock (NASDAQ:BLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioLineRx alerts:Sign Up Key Stats Today's Range$2.87▼$3.0650-Day Range$2.18▼$3.3552-Week Range$2.15▼$7.77Volume55,153 shsAverage Volume33,300 shsMarket Capitalization$13.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management. Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist. Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.AI Generated. May Contain Errors. Read More BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreBLRX MarketRank™: BioLineRx scored higher than 14% of companies evaluated by MarketBeat, and ranked 817th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingBioLineRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -18.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -18.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.66% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 5.09.Change versus previous monthShort interest in BioLineRx has recently increased by 1.78%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for BioLineRx this week, compared to 2 articles on an average week.Search Interest1 people have searched for BLRX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by Insiders1.10% of the stock of BioLineRx is held by insiders.Percentage Held by Institutions1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLRX Stock News HeadlinesBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual MeetingMay 22 at 7:00 AM | prnewswire.comBioLineRx to Report First Quarter 2026 Results on May 27, 2026May 20 at 7:00 AM | prnewswire.comThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off.May 22 at 1:00 AM | Weiss Ratings (Ad)BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived XenograftsMay 19 at 7:00 AM | prnewswire.comBioLineRx (BLRX) Expected to Announce Quarterly Earnings on TuesdayMay 19 at 2:27 AM | americanbankingnews.comBioLineRx (NASDAQ:BLRX) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?May 13, 2026 | americanbankingnews.comBioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)April 28, 2026 | finanznachrichten.deBLRX stock surges pre-market on cancer trial catalyst – eyes 50-DMA breakout for first time in nearly 2 monthsApril 28, 2026 | msn.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $2.77 on January 1st, 2026. Since then, BLRX stock has increased by 10.5% and is now trading at $3.06. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings data on Tuesday, March, 24th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.16. The biotechnology company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.49 million. BioLineRx had a negative trailing twelve-month return on equity of 5.61% and a negative net margin of 99.58%. Read the conference call transcript. When did BioLineRx's stock split? BioLineRx shares reverse split before market open on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA). Company Calendar Last Earnings3/24/2026Today5/22/2026Next Earnings (Estimated)5/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BLRX's financial health is in the Yellow zone, according to TradeSmith. BLRX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.17 million Net Margins-99.58% Pretax Margin-171.70% Return on Equity-5.61% Return on Assets-2.81% Debt Debt-to-Equity Ratio0.19 Current Ratio1.95 Quick Ratio1.78 Sales & Book Value Annual Sales$1.18 million Price / Sales11.28 Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.57Miscellaneous Outstanding Shares4,351,000Free Float4,303,000Market Cap$13.31 million OptionableOptionable Beta1.42 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BLRX) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredDo NOT Buy SpaceX Before Seeing thisThe SpaceX IPO is scheduled for June 12, and CNBC is already calling it 'the big market event of 2026.' For...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
